AI Article Synopsis
- Diamond-Blackfan anemia (DBA) is a rare genetic condition causing bone marrow failure, associated with physical abnormalities and higher cancer risk, linked to mutations in ribosomal protein genes.
- A study used targeted next-generation sequencing on 12 suspected DBA patients to identify novel mutations and analyze clinical outcomes, revealing 11 mutations—5 of which were new.
- The results highlighted differences in physical malformations and treatment responses between patients with specific mutations (RPS10 and RPS26), underlining next-gen sequencing's effectiveness in diagnosing genetic diseases like DBA.
Article Abstract
Introduction: Diamond-Blackfan anemia (DBA) is a rare congenital bone marrow failure syndrome characterized by erythroid aplasia, physical malformation, and cancer predisposition. Twenty ribosomal protein genes and three non-ribosomal protein genes have been identified associated with DBA.
Methods: To investigate the presence of novel mutations and gain a deeper understanding of the molecular mechanisms of disease, targeted next-generation sequencing was performed in 12 patients with clinically suspected DBA. Literatures were retrieved with complete clinical information published in English by November 2022. The clinical features, treatment, and RPS10/RPS26 mutations were analyzed.
Results: Among the 12 patients, 11 mutations were identified and 5 of them were novel (RPS19, p.W52S; RPS10, p.P106Qfs*11; RPS26, p.R28*; RPL5, p.R35*; RPL11, p.T44Lfs*40). Including 2 patients in this study, 13 patients with RPS10 mutations and 38 patients with RPS26 mutations were reported from 4 and 6 countries, respectively. The incidences of physical malformation in patients with RPS10 and RPS26 mutations (22% and 36%, respectively) were lower than the overall incidence in DBA patients (~50%). Patients with RPS26 mutations had a worse response rate of steroid therapy than RPS10 (47% vs. 87.5%), but preferred RBC transfusions (67% vs. 44%, p = 0.0253).
Conclusion: Our findings add to the DBA pathogenic variant database and demonstrate the clinical presentations of the DBA patients with RPS10/RPS26 mutations. It shows that next-generation sequencing is a powerful tool for the diagnosis of genetic diseases such as DBA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.14126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel nonsense RPS26 mutation in a patient with Diamond-Blackfan anemia: a case report.
J Med Case Rep
November 2024
Department of Medical Genetics, Adana Faculty of Medicine, Adana City Education and Research Hospital, University of Health Sciences, Adana, Turkey.
Article Synopsis
- Diamond-Blackfan anemia is a rare genetic disorder linked to mutations in ribosomal protein genes, and this report introduces a new variant in the RPS26 gene that hasn't been previously documented.
- A 16-month-old Turkish girl was diagnosed with the condition, showing symptoms like pallor and macrocytosis, with genetic testing revealing the novel c.221G>T (p.C74F) mutation in the RPS26 gene.
- This discovery highlights the complexity of Diamond-Blackfan anemia's genetic diversity and emphasizes the importance of genetic testing for accurate diagnosis and potential future treatments.
The Diverse Genomic Landscape of Diamond-Blackfan Anemia: Two Novel Variants and a Mini-Review.
Children (Basel)
November 2023
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Diamond-Blackfan anemia (DBA) is a ribosomopathy characterized by bone marrow erythroid hypoplasia, which typically presents with severe anemia within the first months of life. DBA is typically attributed to a heterozygous mutation in a ribosomal protein (RP) gene along with a defect in the ribosomal RNA (rRNA) maturation or levels. Besides classic DBA, DBA-like disease has been described with variations in 16 genes (primarily in , followed by alias , , and ).
View Article and Find Full Text PDFIdentification of novel mutations in patients with Diamond-Blackfan anemia and literature review of RPS10 and RPS26 mutations.
Int J Lab Hematol
October 2023
SINO-US Diagnostics, Tianjin Enterprise Key Laboratory of AI-aided Hematopathology Diagnosis, Tianjin, China.
Article Synopsis
- Diamond-Blackfan anemia (DBA) is a rare genetic condition causing bone marrow failure, associated with physical abnormalities and higher cancer risk, linked to mutations in ribosomal protein genes.
- A study used targeted next-generation sequencing on 12 suspected DBA patients to identify novel mutations and analyze clinical outcomes, revealing 11 mutations—5 of which were new.
- The results highlighted differences in physical malformations and treatment responses between patients with specific mutations (RPS10 and RPS26), underlining next-gen sequencing's effectiveness in diagnosing genetic diseases like DBA.
Translation regulation of specific mRNAs by RPS26 C-terminal RNA-binding tail integrates energy metabolism and AMPK-mTOR signaling.
Nucleic Acids Res
May 2023
Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot 7610001, Israel.
Article Synopsis
- - Increasing evidence indicates that ribosomal protein composition and modifications play a significant role in controlling how proteins are synthesized, particularly in the context of specific mRNAs.
- - Using CRISPR-Cas9 technology, researchers mutated a key ribosomal protein (RPS26), affecting its ability to bind to certain mRNA regions and subsequently influencing translation efficiency based on different start signals (Kozak vs. TISU).
- - The mutated protein (RPS26dC) allowed cells to better withstand energy stress, such as glucose starvation, by altering cellular energy responses and providing insights into how specific ribosomal interactions can impact overall metabolism and mRNA translation under stress conditions.
Deficiency of ribosomal protein S26, which is mutated in a subset of patients with Diamond Blackfan anemia, impairs erythroid differentiation.
Front Genet
December 2022
Department of Health Sciences, Università Del Piemonte Orientale, Novara, Italy.
Diamond Blackfan anemia (DBA) is a rare congenital disease characterized by defective maturation of the erythroid progenitors in the bone marrow, for which treatment involves steroids, chronic transfusions, or hematopoietic stem cells transplantation. Diamond Blackfan anemia is caused by defective ribosome biogenesis due to heterozygous pathogenic variants in one of 19 ribosomal protein (RP) genes. The decreased number of functional ribosomes leads to the activation of pro-apoptotic pathways and to the reduced translation of key genes for erythropoiesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!